Events | 2010.02.05
AMAG Pharmaceuticals Provides Feraheme® Safety Update
LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today provided a safety update on Feraheme® (ferumoxytol) Injection for intravenous use. Since the commercial launch of Feraheme in July 2009, serious adverse events have been reported at a rate consistent
For more information, please visit
http://www.businesswire.com/news/home/20100205005915/en
